From cancer to differentiated cell

Learn more about our unprecedented approach from problem to our solution.

Glioblastoma

is the most common and aggressive malignant primary brain tumour.

  • 40.000 new cases per vear globally
  • GBM tumours are difficult to treat
  • Considered incurable
  • Nearly 100% of patients experience disease relapse after initial treatment

Current standard of care

is of limited benefit and prognosis is poor

  • Surgery. chemotherapy and Radiotherapy
  • There are 4 approved therapies which have had minimal impact on survival - TMZ the only therapy to demonstrate OS benefit (2.5 months)
  • Average survival after diagnosis is 15 months

Our solution: differentiation therapy

Paradigm shift in treating brain cancer

Differentiation therapy turns cancer stem cells into "normal", mature brain cells, thereby rendering them unable to multiply and incapable of perpetuating the tumor

A platform technology leveraging neurobiology of brain stem cells to discover biological drugs that specifically tackle tumorcells, baricularly deeressive cancer stem cells.

The strength of our approach

Distruptive
discovery Plattorm

An unprecedented approach
in the field of tissue cancers

Overcames flaws
in drug discovery

responsible for repeated
failures in neurocology

Pipeline of unconventional
and innovative leads

Standard drug development time reduced by ten folds

Brain Cancer Stem Cell Primary Lines
Surgery Tissue Samples

Definition of new Leads

Data Analysis and Data Quering

Differentional Functional Conditions

Predictive Canditates

Validation

Golden Canditates
Golden candidates
Agonism/Antagonism Strategies

DISCOVERY MODULE

Our Platform is based on the largest collection of brain primary cancer and normal stem cell lines.
By proprietary assays it discovers and validates new leads that tackle specific cell functions in cancer-initiating cells with unprecedented, unmatched prediction ability